Regular monitoring with circulating tumour DNA (ctDNA) has the potential to detect and treat cancer relapse earlier. This study examines the views of patients with early-stage melanoma on the acceptability of the test and early treatment. It concludes that participants were positive about ctDNA monitoring and early treatment and would welcome extra surveillance, as well as trust ctDNA tests.
According to this recent study, FAT atypical cadherin 1 (FAT1) mutations were associated with better immunogenicity and ICI efficacy, which may be considered as a biomarker for selecting patients to receive immunotherapy.
This article aims to provide a comprehensive review of the existing sunscreen testing standards, while providing a critical perspective on associated challenges, demands and opportunities in improving analytical methods for sunscreen testing.
This article describes the detailed clinical and histological features of those lesions that share many similar features with melanoma. Knowledge of these imitators can help pathologists distinguish between benign and malignant cases and avoid misdiagnosis.
According to this recent study, further primary care interventions sensitive to existing workflow arrangements may be required to standardise melanoma risk assessment and management processes.
Teachers are highly influential role models in developing young peoples sun safe routines and practices. According to this recent study, supplementing existing teacher education programs to upskill preservice teachers before they enter schools may provide a sustainable strategy to improve sun safe HPE pedagogies and school sun protection routines.
A skin microbiopsy device developed by researchers at The University of Queensland, that takes tissue samples smaller than 0.5mm in diameter, could change the way skin cancers and other skin conditions are diagnosed and monitored. It allows dermatologists to rapidly collect samples of skin without local anaesthetic or sutures.
How T cell receptor (TCR) signal strength modulates T cell function and to what extent this is modified by immune checkpoint blockade (ICB) are key questions in immunology. Findings of this recent study reveal how analysis of TCR signal strength — and its manipulation — can provide powerful metrics for monitoring outcomes to immunotherapy.
Melanoma Institute Australia (MIA) has developed a new clinical tool to help oncologists more accurately determine if their patients will respond to immunotherapy before starting treatment. Developed by researchers at MIA, the Immunotherapy Outcomes Prediction calculator will help guide treatment decision making.
According to this recent study, newly developed combinations of routinely collected baseline clinical factors predict the response and survival outcomes of patients with metastatic melanoma treated with immunotherapy and may serve as valuable tools for clinical decision making.